The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Signatures of mutational processes in human cancer
Open accessAbstract
All cancers are caused by somatic mutations; however, understanding of the biological processes generating these mutations is limited. The catalogue of somatic mutations from a cancer genome bears the signatures of the mutational processes that have been operative. Here we analysed 4,938,362 mutations from 7,042 cancers and extracted more than 20 distinct mutational signatures. Some are present in many cancer types, notably a signature attributed to the APOBEC family of cytidine deaminases, whereas others are confined to a single cancer class. Certain signatures are associated with age of the patient at cancer diagnosis, known mutagenic exposures or defects in DNA maintenance, but many are of cryptic origin. In addition to these genome-wide mutational signatures, hypermutation localized to small genomic regions, 'kataegis', is found in many cancer types. The results reveal the diversity of mutational processes underlying the development of cancer, with potential implications for understanding of cancer aetiology, prevention and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of TAA-derived epitopes has the advantage of allowing development of an off-the-shelf product for a tumour indication with low mutational burden such as GBM, where patients’ tumours express only few tumour-specific antigens [38].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredIn the citing paper
“In MM, SBS9, associated with mutations introduced by polymerase η repair of activation-induced deaminase (AID) activity26,31,32, was strongly linked with Q61H”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [26]
In the citing paper
“Five substitution and five rearrangement signatures [8, 9] were identified”
From Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers (2019) · cites this paper as [8]
In the citing paper
“a high SNV burden associated with APOBEC substitution signature [8]”
From Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers (2019) · cites this paper as [8]
In the citing paper
“It has also been noted that the 'pol h mutational signature' (Signature 9; http://cancer.sanger.ac.uk/cosmic/sig natures) occurs in chronic lymphocytic leukemia and malignant Bcell lymphoma genomes 6,26,27 .”
From DNA polymerase η mutational signatures are found in a variety of different types of cancer (2018) · cites this paper as [6]
In the citing paper
“Several distinct mutational signatures sculpt the genome of NSCLC – including signatures of tobacco exposure and APOBEC-mediated cytidine deamination57.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [57]
In the citing paper
“Melanoma somatic mutations consist almost entirely of C → T transitions, 28% of which are TCC → T mutations (19,31).”
From Evidence for recent, population-specific evolution of the human mutation rate (2015) · cites this paper as [19]
In the citing paper
“Excess C → T transitions are characteristic of several different mutagenic processes including UV damage and cytosine deamination (19).”
From Evidence for recent, population-specific evolution of the human mutation rate (2015) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationStratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
Self-citationSomatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Self-citationThe Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,541
Self-citationThe mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Cited by
Sorted by citations
Items 601–700 of 1,100
Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B
Shi, K., Carpenter, M. A., Banerjee, S., Shaban, N. M., Kurahashi, K., Salamango, D. J., McCann, J. L., Starrett, G. J., Duffy, J. V., Demir, Ö., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3344 · Cited by 260
Lin, D., Wang, M., & Koeffler, H. P. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.066 · Cited by 249
Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs
Hadi, K., Yao, X., Behr, J. M., Deshpande, A. S., Xanthopoulakis, C., Tian, H., Kudman, S., Rosiene, J. A., Darmofal, M., DeRose, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.006 · Cited by 249
Self-citationTranslational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 255
Subbiah, V., Solit, D. B., Chan, T. A.-T., & Kurzrock, R. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.002 · Cited by 254
Kasar, S. N., Kim, J., Improgo, R., Tiao, G., Polak, P. P., Haradhvala, N. J., Lawrence, M. S., Kieżun, A., Fernandes, S. M., Bahl, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9866 · Cited by 257
Chang, J., Tan, W., Ling, Z., Xi, R., Shao, M., Chen, M., Luo, Y., Zhao, Y., Liu, Y., Huang, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15290 · Cited by 251
Alternative mRNA splicing in cancer immunotherapy
Frankiw, L., Baltimore, D., & Li, G. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0195-7 · Cited by 253
Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangementsPreprint
Zhang, C., Leibowitz, M. L., & Pellman, D. S. (2013) · Genes & Development · doi:10.1101/gad.229559.113 · Cited by 258
Quantification of subclonal selection in cancer from bulk sequencing data
Williams, M. J., Werner, B., Heide, T., Curtis, C. N., Barnes, C. P., Sottoriva, A., & Graham, T. A. (2018) · Nature Genetics · doi:10.1038/s41588-018-0128-6 · Cited by 250
Stratigos, A. J., Garbe, C., Dessinioti, C., Lebbé, C., Bataille, V. A., Bastholt, L., Dréno, B., Fargnoli, M. C., Forsea, A., Frenard, C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.007 · Cited by 247
Origins, genetic landscape, and emerging therapies of small cell lung cancerPreprint
Semenova, E. A., Nagel, R., & Berns, A. J. M. (2015) · Genes & Development · doi:10.1101/gad.263145.115 · Cited by 247
Somatic TP53 Mutations in the Era of Genome SequencingPreprint
Hainaut, P. L., & Pfeifer, G. P. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026179 · Cited by 256
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
Riaz, N., Blecua, P., Lim, R. S., Shen, R., Higginson, D. S., Weinhold, N., Norton, L., Weigelt, B., Powell, S. N., & Reis-Filho, J. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00921-w · Cited by 249
Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines
Russell, S. J., & Barber, G. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.011 · Cited by 253
Chronic lymphocytic leukaemia: from genetics to treatment
Bosch, F., & Dalla‐Favera, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0239-8 · Cited by 259
Hot and cold tumors: Immunological features and the therapeutic strategies
Wang, L., Geng, H., Liu, Y., Liu, L., Chen, Y., Wu, F., Liu, Z., Ling, S., Wang, Y., & Zhou, L. (2023) · MedComm · doi:10.1002/mco2.343 · Cited by 261
Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine
Lipinski, K. A., Barber, L. J., Davies, M. N., Ashenden, M., Sottoriva, A., & Gerlinger, M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2015.11.003 · Cited by 256
Wang, S., Jia, M., He, Z., & Liu, X. (2018) · Oncogene · doi:10.1038/s41388-018-0245-9 · Cited by 247
Mechanisms of APOBEC3 mutagenesis in human cancer cells
Petljak, M., Dananberg, A., Chu, K., Bergstrom, E. N., Striepen, J., von Morgen, P., Chen, Y., Shah, H., Sale, J. E., Alexandrov, L. B., et al. (2022) · Nature · doi:10.1038/s41586-022-04972-y · Cited by 252
Self-citationThe Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
Miller, J. F. A. P., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.007 · Cited by 246
Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy
Murugaesu, N., Wilson, G. A., Birkbak, N. J., Watkins, T. B. K., McGranahan, N., Kumar, S., Abbassi‐Ghadi, N., Salm, M., Mitter, R., Horswell, S. D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0412 · Cited by 246
The Immune Biology of Microsatellite-Unstable Cancer
Kloor, M., & Doeberitz, M. V. K. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.02.004 · Cited by 245
Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma
Bischoff, P., Trinks, A., Obermayer, B., Pett, J. P., Wiederspahn, J., Uhlitz, F., Liang, X., Lehmann, A., Jurmeister, P. S., Elsner, A., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02054-3 · Cited by 249
Identification of cancer driver genes based on nucleotide context
Dietlein, F., Weghorn, D., Taylor-Weiner, A. N., Richters, A., Reardon, B. M., Liu, D., Lander, E. S., Allen, E. M. V., & Sunyaev, S. R. (2020) · Nature Genetics · doi:10.1038/s41588-019-0572-y · Cited by 251
The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression
Espiritu, S. M. G., Liu, L., Rubanova, Y., Bhandari, V., Holgersen, E. M., Szyca, L., Fox, N. S., Chua, M. L. K., Yamaguchi, T. N., Heisler, L. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.029 · Cited by 251
Stenzinger, A., Allen, J. D., Maas, J., Stewart, M. D., Merino, D. M., Wempe, M. M., & Dietel, M. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22733 · Cited by 245
TERT promoter mutations in cancer development
Heidenreich, B., Rachakonda, P. S., Hemminki, K., & Kumar, R. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.005 · Cited by 238
Kwon, M., An, M., Klempner, S. J., Lee, H., Kim, K., Sa, J. K., Cho, H. J., Hong, J. Y., Lee, T., Min, Y. W., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0219 · Cited by 240
Evolutionary biology of high-risk multiple myeloma
Pawlyn, C., & Morgan, G. J. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.63 · Cited by 242
Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis
Osorio, F. G., Huber, A. R., Oka, R., Verheul, M., Patel, S. H., Hasaart, K., de la Fonteijne, L., Varela, I., Camargo, F. D., & van Boxtel, R. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.014 · Cited by 246
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Mardiana, S., & Gill, S. I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00697 · Cited by 240
Genomic and evolutionary classification of lung cancer in never smokers
Zhang, T., Joubert, P., Ansari‐Pour, N., Wei, Z., Hoang, P. H., Lokanga, R. A., Moye, A. L., Rosenbaum, J., González-Pérez, A., Martínez-Jiménez, F., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00920-0 · Cited by 243
Self-citationHuman papillomavirus and the landscape of secondary genetic alterations in oral cancersPreprint
Gillison, M. L., Akagi, K., Xiao, W., Jiang, B., Pickard, R. K. L., Li, J., Swanson, B. J., Agrawal, A. D., Zucker, M., Stache-Crain, B., et al. (2018) · Genome Research · doi:10.1101/gr.241141.118 · Cited by 241
Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma
Lee, J. J.-K., Park, S., Park, H., Kim, S., Lee, J., Lee, J., Youk, J., Yi, K., An, Y., Park, I. K., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.013 · Cited by 233
Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome
Fumagalli, D., Gacquer, D., Rothé, F., Lefort, A., Libert, F., Brown, D. N., Kheddoumi, N., Shlien, A., Konopka, T., Salgado, R., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.032 · Cited by 233
Self-citationChen, Y., Zhang, Y. X., Lv, J.-W., Li, Y.-Q., Wang, Y., He, Q.-M., Yang, X.-J., Sun, Y. H., Mao, Y., Yun, J., et al. (2017) · Theranostics · doi:10.7150/thno.21471 · Cited by 234
Germline selection shapes human mitochondrial DNA diversity
Wei, W., Tuna, S., Keogh, M. J., Smith, K. R., Aitman, T. J., Beales, P. L., Bennett, D., Gale, D. P., Bitner-Glindzicz, M. A. K., Black, G. C. M., et al. (2019) · Science · doi:10.1126/science.aau6520 · Cited by 239
Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides
McGirt, L. Y., Jia, P., Baerenwald, D. A., Duszynski, R. J., Dahlman, K. B., Zic, J. A., Zwerner, J. P., Hucks, D., Dave, U., Zhao, Z., et al. (2015) · Blood · doi:10.1182/blood-2014-11-611194 · Cited by 232
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
Chabanon, R. M., Pedrero, M., Lefèbvre, C., Marabelle, A., Soria, J., & Postel-Vinay, S. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0903 · Cited by 236
Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer
Birkenkamp‐Demtröder, K., Nordentoft, I., Christensen, E., Høyer, S., Reinert, T., Vang, S., Borre, M., Agerbæk, M., Jensen, J. B., Orntoft, T. F., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.01.007 · Cited by 231
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Brown, J. S., Sundar, R., & Lopez, J. S. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.376 · Cited by 243
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Iglesias, V. S., Giuranno, L., Dubois, L. J., Theys, J., & Vooijs, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00267 · Cited by 233
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Maron, S. B., Chase, L. M., Lomnicki, S., Kochanny, S. E., Moore, K. L., Joshi, S. S., Landron, S., Johnson, J., Kiedrowski, L. A., Nagy, R. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1704 · Cited by 232
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
Durham, B. H., Lopez-Rodrigo, E., Picarsic, J. L., Abramson, D. H., Rotemberg, V. M., Munck, S. D., Pannecoucke, E., Lu, S. X., Pastore, A., Yoshimi, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0653-6 · Cited by 231
Biomarker-Guided Development of DNA Repair Inhibitors
Cleary, J. M., Aguirre, A. J., Shapiro, G. I., & D’Andrea, A. D. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.035 · Cited by 239
Genetic and epigenetic characteristics of inflammatory bowel disease-associated colorectal cancer
Rajamäki, K., Taira, A., Katainen, R., Välimäki, N., Kuosmanen, A., Plaketti, R.-M., Seppälä, T. T., Ahtiainen, M., Wirta, E.-V., Vartiainen, E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.042 · Cited by 230
Recent insights into cigarette smoking as a lifestyle risk factor for breast cancer
Kispert, S. E., & McHowat, J. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s129746 · Cited by 89
Overcoming Immune Evasion in Melanoma
Eddy, K., & Chen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238984 · Cited by 243
Overlooked roles of DNA damage and maternal age in generating human germline mutations
Gao, Z., Moorjani, P., Sasani, T. A., Pedersen, B. S., Quinlan, A. R., Jorde, L. B., Amster, G., & Przeworski, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901259116 · Cited by 229
Methods of measurement for tumor mutational burden in tumor tissue
Meléndez, B., Campenhout, C. V., Rorive, S., Remmelink, M., Salmon, I. J., & D’Haene, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.02 · Cited by 238
Ward, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 232
Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
van Zyl, B., Tang, D., & Bowden, N. A. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0336 · Cited by 234
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
Chronic immune response dysregulation in MDS pathogenesis
Barreyro, L., Chlon, T. M., & Starczynowski, D. T. (2018) · Blood · doi:10.1182/blood-2018-03-784116 · Cited by 226
A pan-cancer analysis of synonymous mutations
Sharma, Y., Miladi, M., Dukare, S., Boulay, K., Caudron‐Herger, M., Groß, M., Backofen, R., & Diederichs, S. (2019) · Nature Communications · doi:10.1038/s41467-019-10489-2 · Cited by 229
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 238
Cancers make their own luck: theories of cancer origins
Jassim, A., Rahrmann, E. P., Simons, B. D., & Gilbertson, R. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00602-5 · Cited by 236
Genomic landscape of high-grade meningiomas
Bi, W. L., Greenwald, N. F., Abedalthagafi, M., Wala, J. A., Gibson, W. J., Agarwalla, P. K., Horowitz, P. M., Schumacher, S. E., Esaulova, E., Mei, Y., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0014-7 · Cited by 229
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
Schnell, A., Bod, L., Madi, A., & Kuchroo, V. K. (2020) · Cell Research · doi:10.1038/s41422-020-0277-x · Cited by 234
Integrative pathway enrichment analysis of multivariate omics data
Paczkowska, M., Barenboim, J., Sintupisut, N., Fox, N. S., Zhu, H., Abd-Rabbo, D., Mee, M. W., Boutros, P. C., PCAWG Drivers and Functional Interpretation Working Group, Abascal, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13983-9 · Cited by 236
Self-citationWang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
The influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 234
Burugu, S., Asleh, K., & Nielsen, T. O. (2016) · Breast Cancer · doi:10.1007/s12282-016-0698-z · Cited by 234
The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers
Morris, L. G. T., Chandramohan, R., West, L., Zehir, A., Chakravarty, D., Pfister, D. G., Wong, R. J., Lee, N. Y., Sherman, E. J., Baxi, S. S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1790 · Cited by 230
Somatic genomic changes in single Alzheimer’s disease neurons
Miller, M. B., Huang, A. Y., Kim, J., Zhou, Z., Kirkham, S. L., Maury, E. A., Ziegenfuss, J. S., Reed, H. C., Neil, J. E., Rento, L., et al. (2022) · Nature · doi:10.1038/s41586-022-04640-1 · Cited by 223
Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation
Frick, M., Chan, W., Arends, C. M., Hablesreiter, R., Halik, A., Heuser, M., Michonneau, D., Blau, O., Hoyer, K., Christen, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2184 · Cited by 223
Fujimoto, A., Furuta, M., Shiraishi, Y., Gotoh, K., Kawakami, Y., Arihiro, K., Nakamura, T., Ueno, M., Ariizumi, S.-I., Hà, N. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms7120 · Cited by 223
Self-citationGenomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma
Lin, D., Mayakonda, A., Dinh, H. Q., Huang, P., Lin, L., Liu, X., Ding, L., Wang, J., Berman, B. P., Song, E., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2822 · Cited by 223
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma
Moss, T. J., Qi, Y., Liu, X., Peng, B., Kim, T., Ezzeddine, N., Mosqueda, M. E., Guo, C. C., Czerniak, B. A., Ittmann, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.05.048 · Cited by 224
Dafni, U. G., Tsourti, Z., Vervita, K., & Peters, S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.029 · Cited by 226
Mutational signatures are jointly shaped by DNA damage and repair
Volkova, N. V., Meier, B., González‐Huici, V., Bertolini, S., González, S., Vöhringer, H. S., Abascal, F., Martincorena, I., Campbell, P. J., Gartner, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15912-7 · Cited by 227
Self-citationKarn, T., Denkert, C., Weber, K. E., Holtrich, U., Hanusch, C. A., Sinn, B. V., Higgs, B. W., Jank, P., Sinn, H., Huober, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.015 · Cited by 228
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
CAMCAP Study Group, Wedge, D. C., Gundem, G., Mitchell, T., Woodcock, D. J., Martincorena, I., Ghori, M., Zamora, J., Butler, A. P., Whitaker, H. C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0086-z · Cited by 227
Self-citationZhang, L., Dong, X., Lee, M., Maslov, A. Y., Wang, T., & Vijg, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902510116 · Cited by 222
CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank
Geurts, M. H., de Poel, E., Amatngalim, G. D., Oka, R., Meijers, F. M., Kruisselbrink, E., van Mourik, P., Berkers, G., de Winter-de Groot, K. M., Michel, S., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.01.019 · Cited by 222
Genomic patterns of progression in smoldering multiple myeloma
Bolli, N., Maura, F., Minvielle, S., Gloznik, D., Szalat, R., Fullam, A., Martincorena, I., Dawson, K. J., Samur, M. K., Zamora, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05058-y · Cited by 222
Self-citationPasseron, T., Lim, H. W., Goh, C. ‐., Kang, H. Y., Ly, F., Morita, A., Ocampo Candiani, J., Puig, S., Schalka, S., Wei, L., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17242 · Cited by 221
Enter the Matrix: Factorization Uncovers Knowledge from Omics
Stein-O’Brien, G., Arora, R., Culhane, A. C., Favorov, A. V., Garmire, L. X., Greene, C. S., Goff, L. A., Li, Y., Ngom, A., Ochs, M. F., et al. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.07.003 · Cited by 228
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
Teoh, J. Y., Kamat, A. M., Black, P. C., Grivas, P. D., Shariat, S. F., & Babjuk, M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00578-1 · Cited by 221
Asleh, K., Riaz, N., & Nielsen, T. O. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02476-1 · Cited by 235
Comprehensive T cell repertoire characterization of non-small cell lung cancer
Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14273-0 · Cited by 220
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Planes-Laine, G., Rochigneux, P., Bertucci, F., Chrétien, A.-S., Viens, P., Sabatier, R., & Gonçalvès, A. (2019) · Cancers · doi:10.3390/cancers11071033 · Cited by 227
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Boyiadzis, M. M., Kirkwood, J. M., Marshall, J. L., Pritchard, C. C., Azad, N. S., & Gulley, J. L. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0342-x · Cited by 219
Caswell, D. R., & Swanton, C. (2017) · BMC Medicine · doi:10.1186/s12916-017-0900-y · Cited by 225
Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities
Rabbie, R., Ferguson, P. M., Molina‐Aguilar, C., Adams, D. J., & Robles‐Espinoza, C. D. (2018) · The Journal of Pathology · doi:10.1002/path.5213 · Cited by 233
Memon, D., Schoenfeld, A. J., Ye, D., Fromm, G. J., Rizvi, H. A., Zhang, X., Keddar, M. R., Mathew, D., Yoo, K. J., Qiu, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.013 · Cited by 230
Zhang, H., Christensen, C. L., Dries, R., Oser, M. G., Deng, J., Diskin, B., Li, F., Pan, Y., Zhang, X., Yin, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.11.003 · Cited by 222
Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Birzu, C., French, P. J., Caccese, M., Cerretti, G., Idbaïh, A., Zagonel, V., & Lombardi, G. (2020) · Cancers · doi:10.3390/cancers13010047 · Cited by 229
Viel, A., Bruselles, A., Meccia, E., Fornasarig, M., Quaia, M., Canzonieri, V., Policicchio, E., Urso, E. D., Agostini, M., Genuardi, M., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.022 · Cited by 217
Self-citationMerlevede, J., Droin, N. M., Qin, T., Meldi, K. M., Yoshida, K., Morabito, M., Chautard, É., Auboeuf, D., Fenaux, P., Braun, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms10767 · Cited by 225
Self-citationMarinelli, D., Mazzotta, M., Scalera, S., Terrenato, I., Sperati, F., D'Ambrosio, L., Pallocca, M., Corleone, G., Krasniqi, E., Pizzuti, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2105 · Cited by 225
Tang, B., Zhu, J., Li, J., Fan, K. C., Gao, Y., Cheng, S., Kong, C., Zheng, L., Wu, F., Weng, Q., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00663-1 · Cited by 219
Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology
Becker, A. P., Sells, B. E., Haque, S., & Chakravarti, A. (2021) · Cancers · doi:10.3390/cancers13040761 · Cited by 234
Radon and Lung Cancer: Current Trends and Future Perspectives
Riudavets, M., de Herreros, M. G., Besse, B., & Mezquita, L. (2022) · Cancers · doi:10.3390/cancers14133142 · Cited by 227
Salem, M. E., Puccini, A., Grothey, A. F., Raghavan, D., Goldberg, R. M., Xiu, J., Korn, W. M., Weinberg, B. A., Hwang, J. J., Shields, A. F., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0735 · Cited by 220
Robinson, B. D., Vlachostergios, P. J., Bhinder, B., Liu, W., Li, K., Moss, T. J., Bareja, R., Park, K., Tavassoli, P., Cyrta, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10873-y · Cited by 216
Immunotherapy of multiple myeloma
Minnie, S. A., & Hill, G. R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129205 · Cited by 220
APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication
Hoopes, J. I., Cortez, L. M., Mertz, T. M., Malc, E. P., Mieczkowski, P. A., & Roberts, S. A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.021 · Cited by 215
The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer
Law, E. K., Sieuwerts, A. M., LaPara, K. S., Leonard, B. C., Starrett, G. J., Molan, A. M., Temiz, N. A., Vogel, R. I., Gelder, M. E. M., Sweep, F. C. G. J., et al. (2016) · Science Advances · doi:10.1126/sciadv.1601737 · Cited by 215
Self-citation
Metadata
- Authors
- Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Børresen-Dale, A.-L., Boyault, S., Burkhardt, B., Butler, A. P., Caldas, C., Davies, H. R., Desmedt, C., Eils, R., Eyfjörd, J. E., Foekens, J. A., Greaves, M., Hosoda, F., Hutter, B., Ilicic, T., Imbeaud, S., Imielinski, M., Jäger, N., Jones, D. T. W., Jones, D., Knappskog, S., Kool, M., Lakhani, S. R., López-Otín, C., Martin, S., Munshi, N. C., Nakamura, H., Northcott, P. A., Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J. V., Puente, X. S., Raine, K., Ramakrishna, M., Richardson, A. L., Richter, J., Rosenstiel, P., Schlesner, M., Schumacher, T. N., Span, P. N., Teague, J. W., Totoki, Y., Tutt, A. N. J., Valdés-Mas, R., van Buuren, M. M., van ’t Veer, L., Vincent-Salomon, A., Waddell, N., Yates, L. R., Zucman-Rossi, J., Andrew Futreal, P., McDermott, U., Lichter, P., Meyerson, M., Grimmond, S. M., Siebert, R., Campo, E., Shibata, T., Pfister, S. M., Campbell, P. J., & Stratton, M. R.
- Affiliations
- Wellcome Sanger Institute (GB)
- BC Cancer Agency (CA)
- University of Cambridge (GB)
- Garvan Institute of Medical Research (AU)
- Lund University (SE)
- Oslo University Hospital (NO)
- Justus-Liebig-Universität Gießen (DE)
- Université Libre de Bruxelles (BE)
- German Cancer Research Center (DE)
- Erasmus MC Cancer Institute (NL)
- Inserm (FR)
- Broad Institute (US)
- The University of Queensland (AU)
- Universidad de Oviedo (ES)
- Harvard University (US)
- National Cancer Center Research Institute (JP)
- University of Glasgow (GB)
- Brigham and Women's Hospital (US)
- The Netherlands Cancer Institute (NL)
- Radboud University Medical Center (NL)
- King's College London (GB)
- Christian-Albrechts-Universität zu Kiel (DE)
- Corresponding author
- Stratton, Michael R.
- ORCID
- Alexandrov, Ludmil B.
- Wedge, David C.
- Aparicio, Samuel A. J. R.
- Behjati, Sam
- Biankin, Andrew V.
- Bolli, Niccolò
- Boyault, Sandrine
- Burkhardt, Birgit
- Caldas, Carlos
- Davies, Helen R.
- Desmedt, Christine
- Eils, Roland
- Hutter, Barbara
- Imbeaud, Sandrine
- Imielinski, Marcin
- Jäger, Natalie
- Knappskog, Stian
- Kool, Marcel
- Lakhani, Sunil R.
- Martin, Sancha
- Munshi, Nikhil C.
- Nakamura, Hiromi
- Northcott, Paul A.
- Pajic, Marina
- Papaemmanuil, Elli
- Paradiso, Angelo
- Pearson, John V.
- Raine, Keiran
- Ramakrishna, Manasa
- Richardson, Andrea L.
- Richter, Julia
- Rosenstiel, Philip
- Schlesner, Matthias
- Schumacher, Ton N.
- Span, Paul N.
- Teague, Jon W.
- Totoki, Yasushi
- Tutt, Andrew N. J.
- Waddell, Nicola
- Yates, Lucy R.
- McDermott, Ultan
- Meyerson, Matthew
- Grimmond, Sean M.
- Siebert, Reiner
- Shibata, Tatsuhiro
- Pfister, Stefan M.
- Campbell, Peter J.
- Stratton, Michael R.
- Venue
- Nature
- Published
- 2013-08-14
- Volume
- 500
- Issue
- 7463
- Pages
- 415-421
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3776390
- OpenAlex
- W2152061559
- Cited by
- 9,660
- References
- 67
- Citations by year
- 2026: 384 · 2025: 552 · 2024: 643 · 2023: 854 · 2022: 921 · 2021: 1119 · 2020: 1130 · 2019: 939 · 2018: 873 · 2017: 815 · 2016: 660 · 2015: 421 · 2014: 286 · 2013: 45
- FWCI
- 165.61
- Type
- journal article
- Language
- en
- Update notices
- erratum (2013-10-09)
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- Deutsches Krebsforschungszentrum (69120)
- Wellcome Trust (088340, 093867, 098051)
- Broad Institute
- Canada's Michael Smith Genome Sciences Centre
- Cancer Research UK
- University of Glasgow
- Agence Nationale de la Recherche (ANR-10-LABX-0015)
- Institut National de la Santé et de la Recherche Médicale
- University of New South Wales
- Lunds Universitet
- Universitetet i Oslo
- Háskóli Íslands
- Universitat de Barcelona
- BC Cancer Agency
- Labex Immuno-Oncology
- Medisinske fakultet, Universitetet i Oslo
- Cancer Research UK Cambridge Institute, University of Cambridge
- National Cancer Institute (T32CA009216)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- mutational signatures, somatic mutations, cancer genome, APOBEC cytidine deaminases, kataegis, hypermutation, patient age, cancer etiology, cancer types
- MeSH terms
- Aging, Algorithms, Cell Transformation, Neoplastic, Cytidine Deaminase, DNA, DNA Mutational Analysis, Humans, Models, Genetic, Mutagens, Mutation, Neoplasms, Organ Specificity, Transcription, Genetic, Reproducibility of Results, Mutagenesis, Insertional, Mutagenesis, Sequence Deletion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
